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Background and PurposeaaLow levels of soluble receptor for advanced glycation end pro-
ducts (sRAGE) are associated with three conventional vascular risk factors (3Fs: diabetes, hy-
pertension, and hypercholesterolemia), nondiabetic coronary artery disease, and Alzheimer’s 
disease. However, the association between sRAGE and acute ischemic stroke (AS), especially 
AS without a source of cardioembolism, has not yet been established. 
MethodsaaPatients with AS without a source of cardioembolism (n=259) and age-matched 
controls (n=300) were grouped according to the presence of 3Fs: AS patients with and without 
3Fs (3Fs+ AS and 3Fs- AS, respectively) and controls with and without 3Fs (3Fs+ control and 
3Fs- control, respectively). Levels of sRAGE were analyzed among the four groups. 
ResultsaasRAGE was significantly higher in the controls than in the AS patients (855 pg/mL 
vs. 690 pg/mL, p<0.01). sRAGE was significantly higher in 3Fs- controls (996 pg/mL, p<0.05) 
than in 3Fs+ controls (721 pg/mL), and in AS group regardless of the 3Fs (629 pg/mL in 3Fs- 
and 705 pg/mL in 3Fs+). The lowest tertile of sRAGE was associated with an increased risk of 
AS in the 3Fs- group [adjusted odds ratio (OR) 4.0, 95% confidence interval (CI) 1.6-10.3, p< 
0.01] but not in the 3Fs+ group. The level of sRAGE was also correlated with neurological 
severity in the 3Fs- AS group (r=-0.32, p<0.05) but not in the 3Fs+ AS group. 
ConclusionsaaLow plasma levels of sRAGE is a potential biomarker for the risk of AS and 
may reflect the neurological severity of the condition, especially in subjects without identifi-
able conventional risk factors.  J Clin Neurol  2009;5:126-132
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Introduction 
 
The receptor for advanced glycation end products (RAGE) is 
a multiligand cell-surface protein that is expressed various cell 
types including endothelial cells and neurons.
1,2 The binding 
of a ligand to RAGE stimulates the expression of RAGE it-
self, induces oxidative stress, and effectively modulates se-
veral steps of atherogenesis in diabetes.
3-5 Recent studies have 
also demonstrated an increased expression of the cell-surface 
RAGE in dying neurons after hypoxic-ischemic insults and 
human cerebral ischemia, and suggested that the RAGE-li-
gand interaction causes neuronal cytotoxicity.
6,7 
RAGE also has a circulating truncated variant isoform, sol-
uble RAGE (sRAGE), which corresponds to its extracellular 
domain only.
4,5 Exogenously administered sRAGE has been 
successfully used to antagonize advanced glycation end pro-
ducts (AGE)-RAGE-mediated vascular damage.
8 Accordingly, 
sRAGE may compete with cell-surface RAGE for the ligand, 
thus functioning as a decoy and possibly exerting a cytopro-
tective effect.
4,5,8 
Diabetes mellitus and hypertension are conventional risk 
factors for stroke, and hypercholesterolemia is related to vas-
cular atherothrombosis. Decreased levels of sRAGE are found 
in diabetes mellitus, hypertension, hypercholesterolemia, non-
diabetic coronary artery disease, and Alzheimer’s disease.
9-13 
However, it is not yet known whether patients with acute is- 
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chemic stroke (AS), and especially AS without a source of 
cardioembolism, have lower levels of sRAGE compared to 
healthy subjects, or how plasma sRAGE levels differ accord-
ing to the presence of any of the three conventional vascular 
risk factors (3Fs: diabetes mellitus, hypertension, and hyper-
cholesterolemia). 
To address these issues, we measured the levels of sRAGE 
in AS without source of cardioembolism and compared them 
with levels in age matched controls. In addition, we analyzed 
sRAGE in relation to any of the 3Fs. We next explored the 
relation between sRAGE and atherosclerosis [measured as 
carotid intimal medial thickness (IMT)] and stroke severity. 
 
Methods 
 
We prospectively evaluated 1,582 consecutive patients with 
a suspicion of AS who were admitted to the stroke unit of the 
department of neurology in our hospital between January 2006 
and August 2008. For these, clinical information including 
demographic data, medical history, vascular risk factors, rou-
tine blood tests, neurologic examinations, chest radiography, 
and electrocardiography were obtained, and magnetic reson-
ance imaging (MRI) and/or computer tomography (CT) of 
the brain were performed to screen for AS. All of the patients 
with AS (n=1,427) who had relevant lesions on MRI and/or 
CT underwent magnetic resonance angiography or distal sub-
traction angiography; when clinically indicated, some patients 
also underwent transesophageal echocardiography and/or Hol-
ter monitoring. Patients were then further classified accord-
ing to the criteria of the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST),
14 which defines five etiologic subtypes 
of stroke: 1) large artery atherosclerosis or atherothrombosis 
(LAA), 2) small-vessel occlusion or lacunar (SVO), 3) cardio-
embolic (CE), 4) undetermined etiology or cryptogenic, and 
5) other determined etiology. 
Of the 1,427 AS patients, 329 fulfilled the following in-
clusion criteria: 1) first two subtypes (LAA and SVO) of first-
ever AS, 2) 40-79 years of age at the onset of stroke, and 3) 
admission within the first 48 h after symptom onset. Seventy 
patients were excluded as a result of the following exclusion 
criteria: 1) two or more causes of stroke (n=7), 2) presence of 
transient ischemic attack, intracerebral hemorrhage, postsei-
zure neurological deficit, brain abscess, or tumor (n=9), 3) 
previous history of cerebrovascular disease, presence or his-
tory of thromboembolic events, peripheral vascular disease, 
or cardiovascular disease other than hypertension (n=18), 4) 
specified comorbidities [metastatic malignancy, renal disor-
der (serum creatinine >2.0 mg/dL), autoimmune disorder, or 
hematologic disorder] (n=15), 5) current steroid treatment or 
taking lipid-lowering medication during the previous 3 months 
(n=11), or 6) refusal to participate in the study (n=10). A fi-
nal cohort of 259 cases of first-ever AS without a source of 
cardioembolism was enrolled in the study, of which 190 (73%) 
presented with SVO and 69 (27%) presented with LAA. 
For the control group, 394 age-matched volunteers were re-
cruited from a population that attended a health screening in 
the health-promotion center of our hospital. These participants 
were required to have no neurological deficits or neurologic 
symptoms during the previous 3 months. The same exclu-
sion criteria as for the AS group were applied to the control 
group, which results in 300 age-matched controls being en-
rolled in the study. 
For each patient with AS without a source of cardioembo-
lism, the severity of the neurological deficit was rated at the 
time of admission according to the National Institutes of He-
alth Stroke Scale (NIHSS) score. Of the 259 patients with 
AS, 204 (79%) had mild (score <5) neurological deficits and 
55 (21%) had moderate (score 5-10) to severe (score >10) 
neurological deficits. 
Diabetes mellitus was considered present if the participant 
was normally medicated with insulin or an oral agent, or had 
a fasting glucose level of ≥126 mg/dL. Hypertension was 
defined in patients with a systolic blood pressure of ≥140 
mmHg, a diastolic pressure of ≥90 mmHg (as evidenced by 
at least two consecutive blood pressure measurements after 
20 min rest), currently taking antihypertensive medication, 
or a combination of the three. Hypercholesterolemia was de-
fined by a total cholesterol level of ≥200 mg/dL. 
Blood samples were collected into both plain and ethyle-
nediaminetetraacetic acid (EDTA)-containing tubes after a 
12-h overnight fast within the first 48 h poststroke, as close 
as possible to the time of admission. Blood samples were also 
taken from the control subjects after a 12-h overnight fast. All 
of the samples were centrifuged at 1,500×g for 15 min and 
immediately separated; the serum fraction was used for a li-
pid profile test. One plasma aliquot was used for a glucose test 
and the other was stored at -76℃ and used for sRAGE testing. 
Lipid and glucose levels were measured by an automated 
chemical analyzer (Roche Diagnostics, Mannheim, Germany) 
using the enzymatic colorimetric and hexokinase method. 
Plasma total sRAGE was determined using a commercially 
available enzyme-linked immunoassay kit (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s pro-
tocol. Measurements were performed in duplicate and the 
results were averaged. The intra- and interassay coefficients 
of variation were 7% and 10%, respectively. 
To assess atherosclerosis in AS, ultrasonographic scanning 
of the carotid arteries was performed using an echotomogra-
phic system (Aloka, Tokyo, Japan) with an electrical liner tr-
ansducer (mid frequency 8.0 MHz) in clinically available AS  
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(n=156). Scanning of the extracranial common carotid arte-
ries, the carotid bulbs, and the internal carotid arteries in the 
neck was performed bilaterally. The site of greatest thickness 
including a plaque lesion was sought along the arterial walls. 
Three determinations of IMT were conducted at the site of 
the greatest thickness and two adjacent points (located 1 cm 
up stream and 1 cm downstream of the thickest point). These 
three determinations were averaged to form the mean IMT. 
The greatest value among the six mean IMTs (three from the 
left side and three from the right) was used as the represen-
tative value for each patient.   
The study protocol conformed to the Institutional Guide-
lines for Human Research, and all participants provided writ-
ten informed consent to participate before entry into the study. 
 
Statistics 
The statistical package for SPSS 11.0 (SPSS, Chicago, IL, 
USA) was used for statistical analysis, with the level of sta-
tistical significance set at p<0.05. Plasma levels of sRAGE 
were compared after logarithmic transformation because the 
concentrations were not normally distributed. The mean sRA-
GE levels were compared using Student’s t-test (control vs. 
AS) and analysis of variance (ANOVA), followed by a Sch-
effé post-hoc test (among the four subgroups defined by the 
presence of AS and any of the 3Fs). Categorical variables are 
presented as frequency counts, and intergroup comparisons 
were performed using χ2 tests. 
All of the subjects were categorized into tertiles based on 
their plasma sRAGE level, and the classification was used to 
determine the odds ratio (OR) for AS by multiple logistic re-
gression analysis with adjustment for age (in years), sex, 3Fs, 
current smoking, hyper-low-density lipoprotein cholesterole-
mia, hypo-high-density lipoprotein cholesterolemia, and hy-
pertriglyceridemia. 
 
Results 
 
The demographic characteristics of the subjects are present-
ed in Table 1. The age and sex distributions did not differ 
significantly between the control and AS groups (p>0.05). 
The level of sRAGE was significantly higher in the control 
group than in the AS group (855 pg/mL vs. 690 pg/mL, res-
pectively,  p<0.01)(Fig. 1A). To determine the relationship 
between plasma sRAGE level and 3Fs, those are previously 
reported as having a inverse association with sRAGE, the 
control and AS groups were subdivided according to the 
presence of any of the 3Fs. sRAGE was significantly higher 
in 3Fs- controls than in 3Fs+ controls and in AS regardless 
of the 3Fs (Fig. 1B).  
The question of whether plasma sRAGE can be used as a 
biomarker for the risk of AS was addressed by categorizing 
all of the subjects into tertiles of plasma sRAGE level (low-
est tertile <427 pg/mL, middle tertile 427-780 pg/mL, and 
highest tertile ≥780 pg/mL). AS was more prevalent in the 
lowest tertile group, as shown in Fig. 2. 
The adjusted OR was determined to evaluate sRAGE as 
an independent biomarker for the risk of AS. The OR of AS 
was slightly higher in the lowest and middle tertiles of sRA-
GE than in the highest tertile in the total group (Fig. 3A). To 
further clarify the association between sRAGE and AS, all of 
the participants were subgrouped according to the presence 
of any of the 3Fs. The association between low plasma sRA-
Table 1. Demographic characteristics of patients with acute ischemic stroke (AS) and controls 
Control  AS 
  3Fs* (-) 
(n=146) 
3Fs (+) 
(n=154) 
Total 
(n=300) 
3Fs (-) 
(n=50) 
3Fs (+) 
(n=209) 
Total 
(n=259) 
p 
(control 
vs. AS) 
Mean age [years (range)] 61  (41-79)  062 (40-78)  061 (40-79) 61  (40-78)  062 (42-79)  062 (40-79) ns† 
Male (%) 75  (51)  089 (58) 164  (55) 34  (68) 105  (50) 139  (54) ns‡ 
Diabetes mellitus (%)  00 (0)  027 (18)  027 (9)  00 (0)  076 (36)  076 (29) <0.01‡ 
Hypertension (%)  00 (0)  064 (42)  064 (21)  00 (0) 140  (67) 140  (54) <0.01‡ 
Hypercholesterolemia 
(≥200 mg/dL; %) 
00 (0) 
 
116 (75) 
 
116 (39) 
 
00 (0) 
 
136 (65) 
 
136 (53) 
 
<0.01‡ 
 
Current smoking (%) 23  (16)  034 (22)  057 (19) 20  (40)  045 (22)  065 (25) ns‡ 
Hyper-LDL cholesterolemia 
(≥130 mg/dL; %) 
06 (4) 
 
096 (62) 
 
102 (34) 
 
06 (12) 
 
095 (45) 
 
101 (39) 
 
ns‡ 
 
Hypo-HDL cholesterolemia 
(<40 mg/dL for males 
<50 mg/mL for females; %) 
36 (25) 
 
 
032 (21) 
 
 
068 (23) 
 
 
22 (44) 
 
 
103 (49) 
 
 
125 (48) 
 
 
<0.01‡ 
 
 
Hypertriglyceridemia 
(≥200 mg/dL; %) 
06 (4) 
 
020 (13) 
 
026 (9) 
 
07 (14) 
 
043 (21) 
 
050 (19) 
 
<0.01‡ 
 
*sRAGE related three vascular risk factors (diabetes, hypertension, and hypercholesterolemia) , †t-test, ‡χ2 test. 
ns: not significant, LDL: low densitiy lipoprotein, HDL: high density lipoprotein, sRAGE: soluble receptor for advanced glycation end products.    
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GE level and AS was prominent in the 3Fs- group (adjusted 
OR 4.0, 95% confidence interval 1.6-10.3, p<0.01)(Fig. 3B), 
and was uncertain in the 3Fs+ group (Fig. 3C). 
The relationship between plasma sRAGE level and athero-
sclerosis or neurological severity in AS was assessed by cal-
culating and comparing the correlation coefficients between 
sRAGE and carotid IMT, and sRAGE and NIHSS score. 
Carotid IMT was not significantly correlated with sRAGE in 
any of the AS groups (i.e., total AS, 3Fs+ AS, 3Fs- AS)(Fig. 
4A). In addition, the NIHSS score was not significantly cor-
related with sRAGE in either the total or 3Fs+ AS groups; 
however, it was significantly correlated with sRAGE in the 
3Fs- AS group (r=-0.32, p<0.05)(Fig. 4B). 
 
Discussion 
 
This is the first clinical study to demonstrate that the plasma 
level of sRAGE is lower in AS patients than in subjects with-
out stroke. We also found that a decreased plasma sRAGE is 
an independent biomarker for the risk of AS in 3Fs- subjects. 
These findings are of interest because they suggest that plas-
ma sRAGE level can be used as an identifiable risk factor 
for AS in patients without proven vascular risk factors. 
Two opposing hypotheses exist regarding the relationship 
between plasma sRAGE levels and vascular risk factors or 
disease: one state that they are negatively correlated and the 
other that they are positively correlated. Although the me-
chanism is not yet clear, the former, negative-correlation hy-
pothesis suggests that cardiovascular risk factors or disease 
increase the clearance of AGE ligand/sRAGE complexes or 
inhibit the production of sRAGE.
4,5,9 On the other hand, the 
positive-correlation hypothesis suggests that the disease pro-
cess leads to an excess release of sRAGE from activated en-
dothelial cells; thus, sRAGE may reflect tissue RAGE expres-
sion.
15-17 
In our comparison of AS patients and age-matched con-
trols, we confirmed the occurrence of decreased plasma levels 
of sRAGE in 3Fs+ subjects in the control group, a finding 
that is consistent with previous studies.
4,5,9 Also, our study 
demonstrated a decreased level of sRAGE in AS. More im-
portantly, multiple regression analysis revealed that the ad-
justed OR for AS was higher for the lowest tertile of sRAGE 
than for the highest tertile, especially in the 3Fs- group. These 
findings indicate that decreased plasma levels of sRAGE are 
associated with conventional vascular risk factors, and that 
they are independently associated with AS. 
Circulating sRAGE is generated via the cleavage of cell-
surface RAGE or novel splice variants of RAGE.
4,5 The C-
terminal truncated novel splice variant of RAGE is called en-
dogenous secretory RAGE (esRAGE). It has been reported 
that esRAGE has a ligand-binding domain that is signifi-
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cantly correlated with IMT.
18-21 However, a recent study did 
not find any significant correlation between total sRAGE 
and IMT, a finding that is consistent with our present re-
sults.
21,22 These different findings regarding IMT, of total 
sRAGE and esRAGE, we may consider the effect of other 
variant forms of RAGE those comprise more proportion of 
total sRAGE than esRAGE or insufficiently analyzed extent 
of general atherosclerosis (i.e., the extent of extracranial ca-
rotid atherosclerosis that is closely related to carotid IMT 
was calculated, but the extent of intracranial atherosclerosis 
was not quantitatively analyzed in our study). 
The correlation between sRAGE and NIHSS score was 
significant in 3Fs- AS patients, which suggests that sRAGE 
contributes to the pathogenesis of AS in patients with no 
known vascular risk factors. There may be several reasons 
for the absence of no significant correlation between sRAGE 
and NIHSS score in 3Fs+. First, the medications used only by 
3Fs+ subjects (e.g., diabetes and hypertension medications) 
may affect this relationship. sRAGE expression could be af-
fected by medication dose rather than neurological deficit, 
especially in 3Fs+ AS patients. Second, the plasma sRAGE 
level may reflect the extent of vascular risk factors more po-
Fig. 3. Association between tertiles of 
sRAGE and risk of AS according to the 
presence of any of the 3Fs (A: 3Fs po-
sitive and negative group. B: 3Fs ne-
gative group. C: 3Fs positive group). The 
odds ratio was adjusted for age (in years), 
sex, 3Fs, current smoking, hyper-low-
density lipoprotein cholesterolemia, hy-
po-high-density lipoprotein cholestero-
lemia, and hypertriglyceridemia. sRA-
GE: soluble receptor for advanced glyc-
ation end products, AS: acute ischemic 
stroke. 
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tently than the severity of neurological deficit in the 3Fs+ 
group. For example, a mild neurological deficit with severe 
hypertension and severe diabetes may affect the circulatory 
levels of sRAGE more potently than a severe neurological 
deficit with mild diabetes. Finally, a masking effect caused 
by excess release of sRAGE from activated brain endothelial 
cells or dying neuronal cells may be related to destruction of 
the blood-brain barrier.
6,7,23 In the present study, the portion 
of patients with severe neurological deficits (NIHSS score 
>10) was higher in the 3Fs+ AS group than in the 3Fs- AS 
group, and some of these severely deteriorated patients had 
relatively high sRAGE levels (Fig. 4B). Thus, we postulate 
that within a certain range, decreased levels of sRAGE reflect 
the severity of AS; however, above that range, the excess 
sRAGE that is released from dead or injured cells can mask the 
negative correlation between sRAGE and the severity of AS. 
This study was subject to some limitations. First, because 
of the cross-sectional design, the causal relationship between 
low sRAGE concentration and AS and the mechanism by 
which plasma sRAGE levels are decreased in AS could not 
be determined. In particular, we could not determine whether 
sRAGE affects the future morbidity and severity of stroke in 
3Fs+ subjects who had decreased levels of sRAGE before 
their strokes. Second, we excluded subjects who were taking 
statins during the 3 months before admission. Nonetheless, 
because of the clinical state of subjects, those with diabetes 
and/or hypertension who took medication for these diseases 
were included. Unfortunately, we did not analyze the effects 
of medications on the level of sRAGE. 
Because of these important caveats, prospective longitu-
dinal and intervening studies are required to confirm the role 
of sRAGE as a biomarker for the risk of AS and to clarify its 
pathophysiological effects on AS. 
Overall, our results demonstrate that decreased plasma 
levels of sRAGE are associated with AS due to cerebrovas-
cular atherosclerosis or 3Fs in stroke-free subjects, and that 
there is a negative correlation between sRAGE and neurolo-
gical severity in 3Fs- AS. These findings suggest that decreas-
ed plasma sRAGE contributes to the pathogenesis of AS and 
is a candidate biomarker for the risk of AS, particularly in 
3F- subjects who have no identifiable conventional risk fac-
tors for AS. Further longitudinal and integrated studies are 
required to define the role of sRAGE in the pathogenesis and 
neurological severity of 3Fs+ AS. 
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